The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Erin Crane, MD, MPH
Advertisement
Erin Crane, MD, PhD, is a gynecologist oncologist with Atrium Health in Charlotte, NC.
Articles by Erin Crane, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
